Takeda Biopharmaceuticals India Private Limited showcased its innovative digital healthcare solutions at the G20 Health Working Group meeting held in Goa, India. The event’s focus was on creating a digital health ecosystem, discussing innovations in healthcare, exploring how technology can aid continuing care, and providing digital public health goods. Takeda Biopharmaceuticals presented its digital solutions, including MyPKFit, Synapse, and Athena, at the event.
MyPKFit is an FDA-approved application that offers personalized and interactive prophylaxis treatment options. The application enables both healthcare professionals (HCPs) and patients to monitor factor VIII levels in real-time and adapt their activity decisions accordingly, improving their quality of life. The Synapse platform enhances awareness and knowledge-sharing among healthcare professionals, engaging over 4000 healthcare professionals through scientific exchange and educational initiatives. It aims to identify unmet medical needs, gather insights, and provide patient health improvement-oriented solutions to improve standards of care. The Athena App MVP is a digital health solution that empowers patients to easily track, understand, and communicate simple, robust measures of Quality of Life (QOL).
Takeda Biopharmaceuticals is committed to leveraging digital solutions to transform healthcare and improve patient outcomes. Through their digital innovations, they aim to drive healthcare access, enhance standards of care, and optimize patient benefits. Their participation in the G20 Health Working Group meeting provided an excellent platform to showcase their digital capabilities, explore potential collaborations with G20 member countries and relevant international organizations, and drive digital health innovation and adoption. Takeda Biopharmaceuticals is committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions, with a vision for better health and a brighter future.
